These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38497886)

  • 21. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model.
    Liang L; Yu J; Li J; Li N; Liu J; Xiu L; Zeng J; Wang T; Wu L
    Front Oncol; 2021; 11():711020. PubMed ID: 34621670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating PPT2's role in ovarian cancer prognosis and immunotherapy outcomes.
    Xu H; Zhang Y; Xie Z; Xie XF; Qiao WL; Wang M; Zhao BB; Hua T
    J Ovarian Res; 2024 Oct; 17(1):198. PubMed ID: 39394143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
    Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
    Lv Y; Wu L; Jian H; Zhang C; Lou Y; Kang Y; Hou M; Li Z; Li X; Sun B; Zhou H
    Front Immunol; 2022; 13():997765. PubMed ID: 36275664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.
    Chen SF; Wang LY; Lin YS; Chen CY
    J Ovarian Res; 2024 Sep; 17(1):190. PubMed ID: 39342345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
    Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
    J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying a Novel Eight-NK Cell-related Gene Signature for Ovarian Cancer Prognosis Prediction.
    Li N; Yu K; Huang D; Zhou H; Zeng D
    Curr Med Chem; 2024; 31(12):1578-1594. PubMed ID: 37650393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating bulk and single-cell RNA sequencing data reveals epithelial-mesenchymal transition molecular subtype and signature to predict prognosis, immunotherapy efficacy, and drug candidates in low-grade gliomas.
    Wang C; He Z
    Front Pharmacol; 2023; 14():1276466. PubMed ID: 38053842
    [No Abstract]   [Full Text] [Related]  

  • 33. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
    Cao T; Shen H
    J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Subtype Profiling and Establishment of Prognostic Immune-Related lncRNA Pairs in Human Ovarian Cancer.
    Wang X; Wang J; Yu M
    Comput Math Methods Med; 2022; 2022():8338137. PubMed ID: 35578596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
    Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
    Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
    Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
    J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
    Shen L; Li A; Cui J; Liu H; Zhang S
    J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Activated Dendritic-Cell-Related Gene Signature Indicative of Disease Prognosis and Chemotherapy and Immunotherapy Response in Colon Cancer Patients.
    Ouyang Y; Yu M; Liu T; Suo M; Qiao J; Wang L; Li N
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of the Immune Signatures for Ovarian Cancer Based on the Tumor Immune Microenvironment Genes.
    Shen X; Gu X; Ma R; Li X; Wang J
    Front Cell Dev Biol; 2022; 10():772701. PubMed ID: 35372348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.